Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 485 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nausea Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Community-Led Action Research in Oncology: Improving Symptom Management

NCT03208816
View directory record Official record
Conditions
Chemotherapy-induced Neutropenia, Chemotherapy-induced Nausea and Vomiting, Anxiety, Depression, Fatigue, Neoplasms
Interventions
symptom management program for chemotherapy patients
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 20, 2026, 1:43 PM EDT
Terminated Not applicable Interventional Results available

Reletex for Nausea in GERD Patients

NCT01582100
View directory record Official record
Conditions
Nausea
Interventions
Reletex
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting

NCT00787566
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Intranasal granisetron
Drug
Lead sponsor
Shin Nippon Biomedical Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
The Study Is Managed by Kendle International, in Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 20, 2026, 1:43 PM EDT
Recruiting Not applicable Interventional

Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting

NCT07378839
View directory record Official record
Conditions
Pregnancy Emesis, Nausea
Interventions
Alternate Nostril Breathing
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 20, 2026, 1:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Postoperative Gastric Point of Care Ultrasound (G-POCUS) in Abdominal Surgery

NCT05796063
View directory record Official record
Conditions
Ileus Postoperative, Postoperative Nausea and Vomiting
Interventions
gastric point of care ultrasound
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

NCT02939287
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1, Olanzapine10 mg orally daily on Days -1,0,+1 and +2, Aprepitant plus Olanzapine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 20, 2026, 1:43 PM EDT
Terminated Not applicable Interventional

The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting

NCT04478630
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

NCT03403712
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
36
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 20, 2026, 1:43 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Hyperemesis Gravidarum Risk Reduction With Metformin

NCT07129473
View directory record Official record
Conditions
Hyperemesis Gravidarum
Interventions
Metformin Extended Release Oral Tablet
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)

NCT05319860
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV), Aromatherapy Care
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 20, 2026, 1:43 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

NCT03276026
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Respiratory Conditions Due to Other External Agents
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
Virtua Health, Inc.
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Mount Holly, New Jersey
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 20, 2026, 1:43 PM EDT
Not listed Phase 2 Interventional

Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea

NCT04091789
View directory record Official record
Conditions
Dysmenorrhea, Headache, Migraine, Fatigue, Nausea, Mood Disturbance
Interventions
Pure Femme Tablets
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 20, 2026, 1:43 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea And Vomiting in the Bariatric Surgery Population

NCT06585540
View directory record Official record
Conditions
Post Operative Nausea and Vomiting
Interventions
Amisulpride IV Prevention, Amisulpride IV Treatment, Placebo Preventative, Placebo Treatment
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

NCT00064272
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ginger extract, placebo
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
5
States / cities
South Bend, Indiana • Ann Arbor, Michigan • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Not applicable Interventional

Music Therapy on Nausea and Pain for Autologous Stem Cell

NCT01487031
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Music Therapy, No music therapy
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 20, 2026, 1:43 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

NCT07446439
View directory record Official record
Conditions
Nausea and Vomiting, Obesity
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • San Jose, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 20, 2026, 1:43 PM EDT
Terminated Not applicable Interventional Results available

Enterra Therapy Clinical Study (Gastric Stimulation for Gastroparesis)

NCT00157755
View directory record Official record
Conditions
Gastroparesis
Interventions
Enterra Therapy
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
6
States / cities
San Francisco, California • Washington D.C., District of Columbia • Anderson, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Study of APD421 as PONV Treatment (no Prior Prophylaxis)

NCT02449291
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
APD421, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 20, 2026, 1:43 PM EDT
Withdrawn Phase 4 Interventional

Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis

NCT01326117
View directory record Official record
Conditions
Gastroparesis, Diabetic Gastroparesis, Nausea, Vomiting
Interventions
tadalafil
Drug
Lead sponsor
Mark Feinglos
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Not applicable Interventional

Acupressure in Preventing Nausea and Vomiting in Young Cancer Patients Receiving Chemotherapy

NCT00310063
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
acupressure therapy, sham intervention
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Not applicable Interventional

Nurse-Provided Care or Standard Care in Treating Patients With Pancreatic Cancer

NCT00902733
View directory record Official record
Conditions
Fatigue, Nausea and Vomiting, Pain, Pancreatic Cancer
Interventions
medical chart review, questionnaire administration, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2010 · Synced Oct 20, 2026, 1:43 PM EDT
Withdrawn No phase listed Observational

Identifiable Factors That May Lead to Postoperative Nausea and Vomiting After Simple Laparoscopic Appendectomy

NCT02044640
View directory record Official record
Conditions
Acute Appendicitis
Interventions
Appendectomy
Procedure
Lead sponsor
Brian Kenney
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 20, 2026, 1:43 PM EDT
Recruiting Not applicable Interventional

Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband, With Current ERAS (Enhanced Recovery After Surgery) Protocol to Further Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient Within the First 24 Hours Postoperatively.

NCT07063979
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Bariatric Sleeve Gastrectomy
Interventions
Wearable Transcutaneous electrical Nerve Stimulation unit to mitigate postoperative nausea and vomiting (PONV) in the Bariatric Surgical Patient, A sham device that will mimic the active wearable device. It will look the same, and buzz but will not actually admit a low-leve electric current that would stimulate the nerves.
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

Prevention of Intraoperative Nausea and Vomiting During Cesarean Section

NCT01216410
View directory record Official record
Conditions
Cesarean Delivery
Interventions
Metoclopramide, Phenylephrine infusion, Combination Group
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 20, 2026, 1:43 PM EDT